New drug approvals for 2019: Synthesis and clinical applications

Shuo Yuan; Bin Yu; Hong-Min Liu

doi:10.1016/j.ejmech.2020.112667

New drug approvals for 2019: Synthesis and clinical applications

Eur J Med Chem. 2020 Nov 1:205:112667. doi: 10.1016/j.ejmech.2020.112667. Epub 2020 Jul 29.

Authors

Shuo Yuan¹, Bin Yu², Hong-Min Liu¹

Affiliations

¹ School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Military of Education, Zhengzhou University, Zhengzhou, 450001, China.
² School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Military of Education, Zhengzhou University, Zhengzhou, 450001, China. Electronic address: yubin@zzu.edu.cn.

PMID: 32911308
DOI: 10.1016/j.ejmech.2020.112667

Abstract

48 new drugs including 38 chemical entities (33 new chemical entities, 3 new diagnostic agents, and 2 payloads of antibody drug conjugates) and 10 biologics were approved by the U.S. Food and Drug Administration (FDA) during 2019. These marketed new drugs represent privileged structures and novel action of mechanism, and thus can be served as leads to discover new drugs with the similar biological targets and improved therapeutic efficacy. This review aims to provide an overview regarding the synthetic approaches of 33 new chemical entities approved by the FDA in 2019 and their clinical applications.

Keywords: Chemical synthesis; Clinical applications; New drugs.

Publication types

Review

MeSH terms

Chemistry Techniques, Synthetic*
Drug Approval*
Drug Discovery / legislation & jurisprudence
Humans